Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19

From Table 2e — Dosing Regimens for Remdesivir for Hospitalized Adults and Children (Aged ≥12 Years and Weighing ≥40 kg):

“The doses and indications listed below come from the FDA product information…

For Patients Who Are Not Mechanically Ventilated and/or on ECMO:

• RDV 200 mg IVa on Day 1, then RDV 100 mg IV on Days 2–5
• For patients who do not show clinical improvement after 5 days of therapy, treatment may be extended to up to 10 days.

For Mechanically Ventilated Patients and/or Patients on ECMO:

• RDV 200 mg IVa on Day 1, then RDV 100 mg IV on Days 2–10
• Adverse Events. Generally well tolerated”